Tricida Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
61
- Stock Symbol
-
1T7
- Share Price
-
$0.10
- (As of Monday Closing)
Tricida General Information
Description
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.
Contact Information
Website
www.tricida.comCorporate Office
- 2108 North Street
- Suite 4935
- Sacramento, CA 95816
- United States
Corporate Office
- 2108 North Street
- Suite 4935
- Sacramento, CA 95816
- United States
Tricida Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.10 | $0.12 | $0.10 - $13.52 | $6.27M | 58M | 4.63K | -$2.37 |
Tricida Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 692,957 | 519,791 | 243,381 | 1,598,169 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (116,488) | (159,022) | (249,887) | (170,404) |
| Net Income | (133,912) | (176,566) | (264,791) | (176,813) |
| Total Assets | 93,879 | 168,506 | 351,685 | 371,826 |
| Total Debt | 207,995 | 141,544 | 210,433 | 68,229 |
Tricida Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tricida Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tricida Comparisons
Industry
Financing
Details
00-000
000000
Tricida Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AM-Pharma | Venture Capital-Backed | Utrecht, Netherlands | 00 | 00000 | 00000000000 | 00000 |
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000000 00 | 00000 |
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| Ember Therapeutics | Formerly VC-backed | New York, NY | 00 | 000.00 | 000000000000 | 000.00 |
| Biohaven | Formerly VC-backed | Tortola, VI | 000 | 00000 | 00000000 | 00000 |
Tricida Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tricida Patents
Tricida Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4053179-A1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | Pending | 01-Mar-2021 | 0000000000 | 00 |
| AU-2021431510-A1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | Pending | 01-Mar-2021 | 0000000000 | |
| EP-4301377-A1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | Pending | 01-Mar-2021 | 0000000000 | |
| JP-2024512296-A | Crosslinked poly(allylamine) polymer pharmaceutical composition | Pending | 01-Mar-2021 | 0000000000 | |
| EP-3740201-A4 | Method of treating acid-base disorders | Pending | 04-Jun-2018 | A61K31/785 | 0 |
Tricida Executive Team (19)
| Name | Title | Board Seat |
|---|---|---|
| Gerrit Klaerner Ph.D | Founder, Chief Executive Officer, President & Board Member |
Tricida Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Bonita MD | OrbiMed | Board Member | 000 0000 |
| David Hirsch Ph.D | Longitude Capital | Board Member | 000 0000 |
| Gerrit Klaerner Ph.D | Tricida | Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| Sandra Coufal MD | Sibling Capital Ventures | Board Member | 000 0000 |
Tricida Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Tricida Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tricida ESG
Risk Overview
Risk Rating
Updated April, 04, 2023
40.26 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile
Pharmaceuticals
Industry
00 of 895
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 429
Rank
Percentile
Tricida FAQs
-
When was Tricida founded?
Tricida was founded in 2013.
-
Who is the founder of Tricida?
Gerrit Klaerner Ph.D is the founder of Tricida.
-
Who is the CEO of Tricida?
Gerrit Klaerner Ph.D is the CEO of Tricida.
-
Where is Tricida headquartered?
Tricida is headquartered in Sacramento, CA.
-
What is the size of Tricida?
Tricida has 61 total employees.
-
What industry is Tricida in?
Tricida’s primary industry is Pharmaceuticals.
-
Is Tricida a private or public company?
Tricida is a Public company.
-
What is Tricida’s stock symbol?
The ticker symbol for Tricida is 1T7.
-
What is the current stock price of Tricida?
As of 23-Jan-2023 the stock price of Tricida is $0.10.
-
What is the current market cap of Tricida?
The current market capitalization of Tricida is $6.27M.
-
Who are Tricida’s competitors?
AM-Pharma, Akebia Therapeutics, SAGE Therapeutics, Ember Therapeutics, and Biohaven are some of the 42 competitors of Tricida.
-
What is Tricida’s annual earnings per share (EPS)?
Tricida’s EPS for 12 months was -$2.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
